These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 10435849

  • 1. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
    Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR.
    J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
    [Abstract] [Full Text] [Related]

  • 2. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G.
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 6. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Vieni A, Trimarchi F.
    Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ, Group for Lanreotide Autogel Long-Term Study on Acromegaly.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P.
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [Abstract] [Full Text] [Related]

  • 12. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.
    Cozzi R, Barausse M, Sberna M, Lodrini A, Franzini A, Lasio G, Attanasio R.
    Pituitary; 2000 Dec; 3(4):231-8. PubMed ID: 11788011
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C.
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, Chihara K.
    Endocr J; 2013 Jan; 60(5):651-63. PubMed ID: 23337477
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
    Ambrosio MR, Franceschetti P, Bondanelli M, Doga M, Maffei P, Baldelli R, Tamburrano G, Sicolo N, Giustina A, degli Uberti EC.
    Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
    Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D.
    Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
    [Abstract] [Full Text] [Related]

  • 17. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 18. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.
    Caron P, Tabarin A, Cogne M, Chanson P, Jaquet P.
    Eur J Endocrinol; 2000 Jun; 142(6):565-71. PubMed ID: 10822218
    [Abstract] [Full Text] [Related]

  • 19. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M.
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [Abstract] [Full Text] [Related]

  • 20. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R, Ruchała M, Sawicka J, Kotwicka M, Liebert W, Sowiński J.
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.